A randomized controlled trial of oral melatonin supplementation and breast cancer biomarkers.
A randomized controlled trial of oral melatonin supplementation and breast cancer biomarkers.
复制标题
DOI：
10.1007/s10552-012-9927-8
复制
发表时间：
2012-04
期刊：
影响因子：
--
通讯作者：
Chen WY
中科院分区：
文献类型：
--
作者：
Schernhammer ES;Giobbie-Hurder A;Gantman K;Savoie J;Scheib R;Parker LM;Chen WY
我们检测了绝经后乳腺癌幸存者对褪黑素补充的依从性和对乳腺癌生物标志物(雌二醇、胰岛素样生长因子I(IGF-1)、胰岛素样生长因子结合蛋白3(IGFBP-3)和IGF-1/IGFBP-3比率)的影响。在一项双盲、安慰剂对照研究中，有0-III期乳腺癌病史的绝经后妇女在完成了积极的癌症治疗(包括激素治疗)后，被随机分配到每天服用3毫克褪黑素(n=48)或服用安慰剂，为期4个月。在基线和干预完成后采集血浆样本。主要终点是依从性和雌二醇和IGF-1/IGFBP-3水平的变化。95名女性被随机分为两组(48名服用褪黑激素，47名服用安慰剂)。86名妇女(91%)完成了这项研究，并提供了干预前后的血液。褪黑素耐受性良好，无3/4级毒性，依从性高(89.5%)。总体而言，在有乳腺癌病史的绝经后妇女中，每天服用3毫克褪黑素4个月的疗程不会影响循环中的雌二醇、IGF-1或IGFBP-3水平。两组患者的依从性具有可比性。短期褪黑激素治疗不影响雌二醇和IGF-1/IGBBP-3水平。较长疗程的褪黑素对绝经前妇女的影响尚不清楚。在我们的研究人群中，特别低的基线雌二醇水平可能阻碍了检测褪黑素进一步降低雌二醇效果的能力。
We examined compliance with and the effects of melatonin supplementation on breast cancer biomarkers (estradiol, insulin-like growth factor I (IGF-1), insulin-like growth factor binding protein 3 (IGFBP-3), and the IGF-1/IGFBP-3 ratio) in postmenopausal breast cancer survivors. In a double-blind, placebo-controlled study, postmenopausal women with a prior history of stage 0-III breast cancer who had completed active cancer treatment (including hormonal therapy) were randomly assigned to either 3 mg oral melatonin (n=48) or placebo daily for 4 months. Plasma samples were collected at baseline and after completion of the intervention. The primary endpoints were compliance and change in estradiol and IGF-1/IGFBP-3 levels. 95 women were randomized (48 to melatonin and 47 to placebo). 86 women (91%) completed the study and provided pre and post intervention bloods. Melatonin was well-tolerated without any grade 3/4 toxicity and compliance was high (89.5%). Overall, among postmenopausal women with a prior history of breast cancer, a 4 month course of 3 mg melatonin daily did not influence circulating estradiol, IGF-1, or IGFBP-3 levels. Compliance was comparable between the two groups. Short-term melatonin treatment did not influence estradiol and IGF-1/IGBBP-3 levels. Effects of longer courses of melatonin and among premenopausal women are unknown. The particularly low baseline estradiol levels in our study population may have hindered the ability to detect any further estradiol lowering effects of melatonin.
登录
查看更多内容
影响因子：
51.1
作者：
Key, Timothy J.;Appleby, Paul N.;Reeves, Gillian K.;Roddam, Andrew W.
通讯作者：
Roddam, Andrew W.
影响因子：
6.2
作者：
Breen, Nancy;Gentleman, Jane F.;Schiller, Jeannine S.
通讯作者：
Schiller, Jeannine S.
影响因子：
5.4
作者：
Sinisi, AA;Pasquali, D;Bellastella, A
通讯作者：
Bellastella, A
影响因子：
10.4
作者：
Graham, C;Cook, MR;Sastre, A
通讯作者：
Sastre, A
DOI：
10.1093/jnci/83.20.1488
发表时间：
1991-10-16
期刊：
JOURNAL OF THE NATIONAL CANCER INSTITUTE
影响因子：
--
作者：
JORDAN, VC;FRITZ, NF;TORMEY, DC
通讯作者：
TORMEY, DC